Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : Livforsakringsbolaget Skandia Omsesidigt Has Trimmed Citizens Financial Group (CFG) Holding; 3 Analysts Are Bullish Ophthotech (OPHT) Last Week

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2017 | 10:24am CEST

Among 12 analysts covering Ophthotech Corporation, 3 have Buy rating, 0 Sell and 9 Hold. Therefore 25% are positive. Ophthotech Corporation had 24 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has Buy rating by Suntrust Robinson given on Friday, January 8. Chardan Capital Markets maintained Ophthotech Corp (NASDAQ:OPHT) on Monday, December 14 with Buy rating. Cowen & Co downgraded the shares of OPHT in report on Monday, December 12 to Market Perform rating. Chardan Capital Markets maintained the shares of OPHT in report on Wednesday, July 26 with Hold rating. The firm has Overweight rating by JP Morgan given on Thursday, June 2. The firm has Hold rating given on Monday, December 12 by SunTrust. The firm earned Buy rating on Thursday, January 7 by SunTrust. Chardan Capital Markets maintained Ophthotech Corp (NASDAQ:OPHT) rating on Tuesday, August 4. Chardan Capital Markets has Buy rating and $105 target. As per Tuesday, December 13, the company rating was downgraded by Gabelli. The rating was upgraded by Goldman Sachs to Neutral on Tuesday, December 13. See Ophthotech Corp (NASDAQ:OPHT) latest ratings:

26/07/2017 Broker: Chardan Capital Markets Rating: Hold New Target: $3.0000 Maintain

Livforsakringsbolaget Skandia Omsesidigt decreased Citizens Financial Group (CFG) stake by 88.56% reported in 2016Q4 SEC filing. Livforsakringsbolaget Skandia Omsesidigt sold 191,148 shares as Citizens Financial Group (CFG)s stock declined 8.64%. The Livforsakringsbolaget Skandia Omsesidigt holds 24,700 shares with $880,000 value, down from 215,848 last quarter. Citizens Financial Group now has $16.55B valuation. The stock increased 0.73% or $0.24 on August 18, reaching $33.06. About shares traded. Citizens Financial Group Inc (NYSE:CFG) has risen 50.96% since August 21, 2016 and is uptrending. It has outperformed by 34.26% the S&P500.

The stock increased 1.82% or $0.05 on August 18, reaching $2.8. About shares traded. Ophthotech Corp (NASDAQ:OPHT) has declined 94.82% since August 21, 2016 and is downtrending. It has underperformed by 111.52% the S&P500.

Ophthotech Corporation is a biopharmaceutical company. The company has market cap of $100.64 million. The Firm is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. It currently has negative earnings. The Companys primary focus is developing therapeutics for age-related macular degeneration , which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Since April 1, 2017, it had 0 insider buys, and 2 insider sales for $28,065 activity. Another trade for 7,388 shares valued at $26,301 was sold by SBLENDORIO GLENN. $1,764 worth of stock was sold by Redlick David E on Tuesday, June 13.

Investors sentiment decreased to 0.69 in 2016 Q4. Its down 0.46, from 1.15 in 2016Q3. It worsened, as 84 investors sold Ophthotech Corp shares while 28 reduced holdings. 33 funds opened positions while 44 raised stakes. 20.03 million shares or 40.43% less from 33.63 million shares in 2016Q3 were reported. State Of Wisconsin Inv Board accumulated 275,000 shares. Prescott Cap Management holds 0.49% of its portfolio in Ophthotech Corp (NASDAQ:OPHT) for 480,036 shares. Atwood And Palmer Incorporated has invested 0% of its portfolio in Ophthotech Corp (NASDAQ:OPHT). Price T Rowe Md invested 0% in Ophthotech Corp (NASDAQ:OPHT). Pictet Asset Management Limited accumulated 53,042 shares. Royal National Bank Of Canada invested in 0% or 17,813 shares. Alliancebernstein Limited Partnership invested in 43,140 shares. First Allied Advisory Ser, Missouri-based fund reported 15,000 shares. Voloridge Mngmt reported 0.01% of its portfolio in Ophthotech Corp (NASDAQ:OPHT). Brandywine Glob Inv Mgmt Limited Liability Corp has invested 0% in Ophthotech Corp (NASDAQ:OPHT). Airain has invested 0.01% in Ophthotech Corp (NASDAQ:OPHT). Bnp Paribas Arbitrage Sa reported 1,130 shares. California State Teachers Retirement Sys, a California-based fund reported 62,552 shares. Gam Hldg Ag has 60,300 shares for 0.01% of their portfolio. Goldman Sachs accumulated 0% or 154,812 shares.

Among 23 analysts covering Citizens Financial Group (NYSE:CFG), 9 have Buy rating, 2 Sell and 12 Hold. Therefore 39% are positive. Citizens Financial Group had 53 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has Buy rating by Goldman Sachs given on Monday, January 11. Credit Suisse maintained Citizens Financial Group Inc (NYSE:CFG) rating on Wednesday, October 14. Credit Suisse has Neutral rating and $26 target. Barclays Capital maintained Citizens Financial Group Inc (NYSE:CFG) rating on Tuesday, January 3. Barclays Capital has Equal Weight rating and $39 target. On Wednesday, July 22 the stock rating was maintained by Compass Point with Buy. The stock has Sell rating by Zacks on Friday, August 21. Citigroup maintained the stock with Hold rating in Monday, April 24 report. The stock of Citizens Financial Group Inc (NYSE:CFG) earned Hold rating by Sandler ONeill on Monday, November 14. The stock of Citizens Financial Group Inc (NYSE:CFG) earned Mkt Perform rating by Bernstein on Wednesday, November 16. As per Friday, August 11, the company rating was maintained by Jefferies. The firm has Outperform rating by Wedbush given on Friday, October 7.

Since February 28, 2017, it had 1 insider buy, and 0 sales for $523 activity. $523 worth of stock was bought by HIGDON LEO I JR on Tuesday, February 28.

(c) 2017 Daily Tribune. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPHTHOTECH CORP
08/22 OPHTHOTECH : Livforsakringsbolaget Skandia Omsesidigt Has Trimmed Citizens Finan..
08/15 OPHTHOTECH : Announces Results from Third Phase 3 Trial of Fovista in Wet Age Re..
08/14 OPHTHOTECH CORPORATION (NASDAQ : OPHT) Files An 8-K Other Events
08/14 OPHTHOTECH CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
08/14 OPHTHOTECH : Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-R..
08/03 OPHTHOTECH : Reports Second Quarter 2017 Financial and Operating Results
08/03 OPHTHOTECH : Expands Focus with Development for Ophthalmic Orphan Diseases
08/02 OPHTHOTECH : Management's Discussion and Analysis of Financial Condition and Res..
07/28 OPHTHOTECH : How These Biotech Stocks are Performing? -- Inovio Pharma, Intra Ce..
07/27 OPHTHOTECH : Expands Focus with Development for Ophthalmic Orphan Diseases
More news
News from SeekingAlpha
08/21 OPHTHOTECH : 3 Strikes And It's Out?
08/18 SNIPPET ROUNDUP : Transparency For Straumann But A Black Box For Pfizer
08/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 16, 2017
08/14 PREMARKET LOSERS AS OF 9 : 05 am
08/14 Ophthotech's Fovista flunks late-stage in wet AMD; shares down 14% premarket
Financials ($)
Sales 2017 95,8 M
EBIT 2017 5,54 M
Net income 2017 6,66 M
Finance 2017 154 M
Yield 2017 -
P/E ratio 2017 3,40
P/E ratio 2018
EV / Sales 2017 -0,58x
EV / Sales 2018 -0,97x
Capitalization 98,5 M
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 3,70 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Glenn P. Sblendorio President & Chief Executive Officer
David R. Guyer Executive Chairman
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll Chief Financial Officer & Treasurer
Axel Bolte Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-42.03%98
AMGEN16.32%124 096
CELGENE CORPORATION10.09%101 932
GILEAD SCIENCES0.70%95 777
REGENERON PHARMACEUTICALS27.48%51 288
VERTEX PHARMACEUTICALS111.05%39 199